Compare PRAA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAA | AUTL |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United Kingdom |
| Employees | 170 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.9M | 596.2M |
| IPO Year | 2002 | 2025 |
| Metric | PRAA | AUTL |
|---|---|---|
| Price | $20.11 | $1.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.50 | $8.50 |
| AVG Volume (30 Days) | 346.4K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $1,201,837,000.00 | $10,120,000.00 |
| Revenue This Year | $2.01 | $80.32 |
| Revenue Next Year | $2.53 | $53.96 |
| P/E Ratio | $9.19 | ★ N/A |
| Revenue Growth | 7.83 | ★ 496.00 |
| 52 Week Low | $10.25 | $1.18 |
| 52 Week High | $22.55 | $2.58 |
| Indicator | PRAA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | N/A |
| Support Level | $16.53 | N/A |
| Resistance Level | $21.49 | N/A |
| Average True Range (ATR) | 0.81 | 0.00 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 59.58 | 0.00 |
PRA Group Inc is a specialty finance company engaged in the purchase, collection, and management of nonperforming loan portfolios. The majority of the loans it purchases are from credit originators who have chosen not to pursue, or have been unsuccessful in collecting, the full balance owed to them (Core accounts). To a lesser extent, the company also purchases loans in situations where the customer is involved in a bankruptcy or similar proceeding (Insolvency accounts). As part of an ancillary business, it also purchases and provides fee-based services for class action claims recoveries in the U.S. The company has two operating and reportable segments, comprised of its U.S. and European businesses. The majority of its revenue is generated from the United States.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.